Fortress Biotech, Inc.
FBIO
$1.63
-$0.01-0.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -3.48% | -1.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.36% | -1.79% | |||
| Cost of Revenue | -17.34% | -23.32% | |||
| Gross Profit | 2,985.29% | 97.64% | |||
| SG&A Expenses | 5.36% | 5.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.82% | -8.27% | |||
| Operating Income | 13.56% | 12.11% | |||
| Income Before Tax | 2.43% | 7.63% | |||
| Income Tax Expenses | 386.96% | -- | |||
| Earnings from Continuing Operations | 1.42% | 7.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 41.39% | -22.65% | |||
| Net Income | 47.42% | -17.53% | |||
| EBIT | 13.56% | 12.11% | |||
| EBITDA | 14.96% | 11.73% | |||
| EPS Basic | 51.40% | -4.86% | |||
| Normalized Basic EPS | 382.06% | -177.42% | |||
| EPS Diluted | 51.40% | -4.86% | |||
| Normalized Diluted EPS | 382.06% | -177.42% | |||
| Average Basic Shares Outstanding | 32.06% | 7.54% | |||
| Average Diluted Shares Outstanding | 32.06% | 7.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | 1.00% | |||